Comparison 2. ICS dose reduction versus no change in ICS dose (concomitant LABA).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Exacerbation requiring OCS	2	569	Odds Ratio (M‐H, Random, 95% CI)	1.31 [0.82, 2.08]
2 Asthma control (short asthma morbidity score), change from baseline	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Asthma control (Asthma Severity Questionnaire)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4 All‐cause SAEs	2	569	Odds Ratio (M‐H, Random, 95% CI)	0.60 [0.11, 3.33]
5 EuroQoL score (change from baseline)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6 St. George's Respiratory Scale score (change from baseline)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7 Lung function, PEFR morning (L/min) (change from baseline)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
8 Lung function, reduction in FEV1 (% predicted, change from baseline)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
9 Exacerbation requiring hospitalisation	2	569	Odds Ratio (M‐H, Random, 95% CI)	4.06 [0.45, 36.86]
10 Exacerbation requiring ED visit	1		Odds Ratio (M‐H, Random, 95% CI)	Totals not selected
11 Mortality	1	310	Odds Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]